Phase 2 trial of therapy for LRRK2-linked Parkinson’s may open soon
An upcoming Phase 2 clinical trial is due to test NEU-411, a brain-penetrant oral small molecule that Neuron23 is developing to slow the progression of Parkinson’s in people with early-stage disease who carry variations in